EXAS vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXEL, RGEN, HALO, and MDGL
Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
Exact Sciences vs.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk.
Alnylam Pharmaceuticals received 157 more outperform votes than Exact Sciences when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 73.05% of users gave Exact Sciences an outperform vote.
Alnylam Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 1.4% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Exact Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals currently has a consensus price target of $298.61, suggesting a potential upside of 21.25%. Exact Sciences has a consensus price target of $72.94, suggesting a potential upside of 40.97%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Exact Sciences is more favorable than Alnylam Pharmaceuticals.
Exact Sciences has a net margin of -7.95% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Exact Sciences' return on equity.
In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 18 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 0.76 beat Exact Sciences' score of 0.75 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Summary
Exact Sciences beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Exact Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exact Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:EXAS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free EXAS Stock Alerts